Veradermics
NYSE: MANEWest Hartford, US · Founded 2021 · Delaware corporation · 4 known investors
Veradermics is developing VDPHL01, an extended-release oral minoxidil tablet intended as a non-hormonal prescription treatment for pattern hair loss in women and men. The therapy is being evaluated in Phase 2 and Phase 3 clinical trials.
Founders & leadership
Veradermics was founded in 2021 by Reid Waldman.
RW
Reid WaldmanChief Executive Officer and Board Member30 Under 30 2024
TD
Tim DursoChief Technical Officer
DC
Dominic CarranoChief Financial Officer and Treasurer
MN
Mark NeumannChief Commercial and Strategy Officer
JW
John W. ChildsNamed on SEC filing
JG
Jane Grant-KelsNamed on SEC filing
VC
Vladimir CoricNamed on SEC filing
TD
Timothy DursoNamed on SEC filing
Investors · 4
Reported raises · per SEC filings
Form D private placements$269.3M disclosed across 6 rounds · 2020–2026
▶$30MraisedMay 2026 · 2 investors · Other Health CareRule 506(b)
▶$30MraisedMay 2026 · 2 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- PATRICK ENRIGHTDirector
- DAVID FRIEDMANDirector
- JOHN CHILDSDirector
- JANE GRANT-KELSDirector
- VLADIMIR CORICDirector
- MICHAEL GRECOExecutive Officer
- REID WALDMANExecutive Officer, Director
- KATARINA PANCEDirector
- MARK NEUMANNExecutive Officer
- DOMINIC CARRANOExecutive Officer
- TIM DURSOExecutive Officer
- Offering amount
- $30M
- Amount sold
- $30M
- Sales commissions
- $1.8M
- Placement agents
- JEFFERIES LLC, LEERINK PARTNERS LLC, CITIGROUP GLOBAL MARKETS INC., CANTOR FITZGERALD & CO., LIFESCI CAPITAL, NEEDHAM & COMPANY, LLC
- First sale
- May 2026
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
▶$135MraisedOct 2025 · 40 investors · Other Health CareRule 506(b)
▶$135MraisedOct 2025 · 40 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Patrick EnrightDirector
- Katarina PanceDirector
- Amanda Birdsey-BensonDirector
- John ChildsDirector
- Vladimir CoricDirector
- Jane Grant-KelsDirector
- Reid WaldmanExecutive Officer, Director
- Offering amount
- $150M
- Amount sold
- $135M
- First sale
- Oct 2025
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
▶$66.6MraisedDec 2024 · 40 investors · Other Health CareRule 506(b)
▶$66.6MraisedDec 2024 · 40 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Jane Grant-KelsDirector
- Reid WaldmanExecutive Officer, Director
- Amanda Birdsey-BensonDirector
- Christopher EklundDirector
- Vladimir CoricDirector
- Patrick EnrightDirector
- John W. ChildsDirector
- Offering amount
- $75M
- Amount sold
- $66.6M
- First sale
- Nov 2024
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
▶$15MraisedMay 2023 · 16 investors · Other Health CareRule 506(b)
▶$15MraisedMay 2023 · 16 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- John W. ChildsDirector
- Reid WaldmanExecutive Officer, Director
- Jane Grant-KelsDirector
- Vladimir CoricDirector
- Timothy DursoExecutive Officer, Director
- Offering amount
- $15M
- Amount sold
- $15M
- First sale
- Apr 2023
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
▶$22.2MraisedOct 2021 · 41 investors · Other Health CareRule 506(b)
▶$22.2MraisedOct 2021 · 41 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Vladimir CoricDirector
- Reid WaldmanExecutive Officer, Director
- Jane Grant-KelsDirector
- John W. ChildsDirector
- Timothy DursoExecutive Officer, Director
- Offering amount
- $22.2M
- Amount sold
- $22.2M
- First sale
- Sep 2021
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
▶$476.1KraisedOct 2020 · 1 investors · Other Health CareRule 506(b)
▶$476.1KraisedOct 2020 · 1 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Timothy DursoExecutive Officer, Director
- Reid WaldmanExecutive Officer, Director
- Offering amount
- $1.5M
- Amount sold
- $476.1K
- First sale
- Sep 2020
- Incorporated
- Corporation, Texas, 2020
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 3
by search overlapAllure51 shared keywordsAllure is a beauty media brand publishing editorial content on makeup, skincare, hair, and celebrity beauty news, along with product reviews and a subscription beauty product box. It also operates the Allure Beauty Box, a curated monthly beauty product subscription service.
Hims & Hers45 shared keywordsUS direct-to-consumer telehealth company selling prescription and OTC treatments online by subscription; NYSE-listed as HIMS.
Ro29 shared keywordsRo is an online healthcare platform that connects patients with licensed providers and delivers prescription treatments, including GLP-1 medications for weight loss, ED treatments, and other health goals. The direct-to-consumer telehealth service is fully online and serves individual patients in the United States.
Companies competing with Veradermics for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Veradermics Tumbles as Lock-Up Expiry Spooks Investors - TipRanks.comtipranks.com · Aug 2026
MANE Stock Draws Traders As Volatility And Cash Pile Stand Out - StocksToTradestockstotrade.com · Jul 2026Frequently asked questions
- What does Veradermics do?
- Veradermics is developing VDPHL01, an extended-release oral minoxidil tablet intended as a non-hormonal prescription treatment for pattern hair loss in women and men. The therapy is being evaluated in Phase 2 and Phase 3 clinical trials.
- Who founded Veradermics?
- Veradermics was founded by Reid Waldman in 2021.
- Who are Veradermics's investors?
- Veradermics's investors include Longitude Capital, Connecticut Innovations, OUP (Osage University Partners), SR One Capital Management.
- How much funding has Veradermics raised?
- Veradermics has disclosed $269.3M raised across 6 rounds.
- Where is Veradermics headquartered?
- Veradermics is headquartered in West Hartford, US.